# Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

> **NCT05517447** · PHASE3 · TERMINATED · sponsor: **Immunovant Sciences GmbH** · enrollment: 109 (actual)

## Conditions studied

- Thyroid Eye Disease

## Interventions

- **OTHER:** Observational cohort study
- **DRUG:** Batoclimab

## Key facts

- **NCT ID:** NCT05517447
- **Lead sponsor:** Immunovant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-06
- **Primary completion:** 2026-04-02
- **Final completion:** 2026-04-02
- **Target enrollment:** 109 (ACTUAL)
- **Why stopped:** The feeder studies (i.e., IMVT-1401-3201 and 3202) for study IMVT-1401-3203 failed to achieve their pre-defined primary efficacy outcomes. Accordingly, there was a change to the benefit-risk balance. No new safety findings were observed.
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05517447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05517447, "Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05517447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*